Synthetic Liposomal Curcumin – LIPOCURCTM

Curcumin-like compounds are found in a genus of root vegetables that includes turmeric and ginger; they have been consumed for thousands of years and epidemiological evidence suggests various health benefits. Historically, development of Curcumin as a pharmaceutical product has been hampered by Curcumin’s two major flaws; poor absorption and cardiac side effects. Curcumin in its natural form is very poorly absorbed and only very limited amounts get into the body when administered orally. If Curcumin is administered intravenously to achieve higher blood levels, it causes significant cardiac arrhythmia side effects. Signpath’s proprietary liposomal synthetic Curcumin formulation (LipoCurcTM) solves both of these issues, achieving high bioavailability (over 1000 times higher than oral Curcumin) without causing cardiac arrhythmia side effects.

More Details

2

Phase 1 clinical trials successfully completed. (Phase 1a and Phase 1b)

70

Human Subjects Have Received LipoCurc With Minimal Toxicity and signs of Efficacy

II

Preparing for Phase II Studies in Glioblastoma and Multiple Myeloma

A patient with metastatic colon cancer who had received seven prior lines of multi-drug chemotherapy exhibits significant reduction in cancer markers as a result of LipoCurc treatment

Mechanisms of Glioblastoma-Induced Immunosuppression

Glioblastomas and other cancers adapt to treatment (chemotherapy, radiation therapy, vaccines, CAR-T therapy) by inducing severe immunosuppression in the patient, and are thus able to escape the effects of treatment. They secrete proteins (PD-L1, PD-L2, B7), which can bind to T cells and signal a reduced immune response, or enzymes (IDO) which cause unbalanced tryptophan metabolism and production of immunotoxic metabolites. Immune checkpoint inhibitors on the market block either the binding of PD-L1 or PD-L2 to PD-1 on the T cell or the binding of B7 to CTLA-4 , Liposomal curcumin blocks each of these immunosuppessive pathways and also reduces the production of IDO.

Cancer Indications Currently In Clinical Development

Signpath has successfully completed Phase 1a and Phase 1b human clinical trials using LipoCurcTM. These clinical trials have shown LipoCurcTM to be safe at clinical doses, with minimal adverse side effects. The Phase 1b trial showed significant signs of efficacy in several heavily pre-treated salvage patients.

Two very heavily pretreated patients had major reductions in cancer markers. A patient with metastatic colon cancer who had received seven prior lines of multi-drug chemotherapy had a reduction in his CEA from 18,542 to 6,441 and a decrease in CA 19-9 from18,105 – 13,238. A patient with metastatic prostate carcinoma who had also received seven prior lines of therapy showed a reduction of his PSA from 649 t0 350 and of his LDH from 435 to 220. It is very rare to see evidence of response in cancer patients with solid tumors even after four or five previous lines of therapy.

Using the data generated from the Phase 1 trials, we are preparing for two Phase 2 trials; one in glioblastoma and the other in multiple myeloma.

Glioblastoma as a Target for Liposomal Curcumin

Glioblastoma, is the most common primary brain tumor, and has few available therapies providing significant improvement in survival. Glioblastoma has the highest number of cases of primary malignant tumors of the brain, with over 14,000 new cases annually in the United States. Additionally, glioblastoma patients have limited survival with current treatment, allowing for rapid evaluation of endpoint criteria. The market for glioblastoma alone is projected at over $3 billion by 2024.

Unlike most pharmaceutical agents, LipoCurcTM passes the blood/brain barrier and is able to access brain tissue. LipoCurcTM acts through multiple pathways, including immunomodulation. Glioblastoma tumors are not normally sensitive to the body’s natural immunity. Glioblastomas adapt to treatment by causing secretion of immune checkpoint molecules that use four major pathways (PD-L1/PD-1; PD-L2/PD-1; B7/CTLA4; IDO) to prevent the patient from mounting an immune response. Unlike other immuno-oncology agents, LipocurcTM has minimal side effects.

Multiple Myeloma as a Target for Liposomal Curcumin

Multiple Myeloma is a cancer of the blood, with a current $8 billion market size. LipoCurcTM accumulates in the blood cells, making it particularly well suited for targeting blood cancers. Multiple myeloma is a cancer of plasma cells, a type of white blood cell. Lipocurc concentrates intensely in malignant and leukemic white blood cells, and preferentially destroys these cancerous cells. Signpath is currently engaged in study design and site selection for a Phase 2 trial of LipoCurcTM in Multiple Myeloma.

Mechanism of Action

The mechanism of action of LipoCurcTM is in part due to curcumin activation of sphingomyelinase leading to an increased ceramide/S1P ratio. The increased ceramide activates growth inhibition and cell death mechanisms. Ceramide is an N-acylsphingosine consisting of a fatty acid bound to the amino group of the sphingoid base, sphingosine. As an agent of cell signaling, ceramide activates a variety of protein kinases. Differential activation of these proteins determines the nature of the signal and its effect on the cell. Generally, in cancer cells ceramides favor anti-proliferative and cell death pathways (such as senescence and apoptosis). Curcumin stimulates ceramide production, which leads to cancer cell death through apoptosis.

Curcumin also has an inhibitory effect on tumor stem cells which may contribute to its proposed clinical benefit.

There are molecular based reasons for using liposomal curcumin as a treatment for cancer. Brain tumors, including glioblastoma, exhibit distinct patterns of cancer gene mutations of the IDH1 gene, which functions as a tumor suppressor. IDH1 gene mutations have been shown to drive tumor formation and progression in glioblastomas. When the IDH1 gene is mutated, it causes over expression of Hypoxia-inducible factor 1 (HIF-1) which stimulates tumor growth and metastasis. Curcumin inhibits over expression of HIF-1.

Osteopontin (OPN) is a secreted protein involved in most aspects of tumor progression and metastasis development. Elevated OPN expression has been reported in the highest grade and most aggressive glioblastomas. Curcumin inhibits osteopontin, which provides another rationale for anti-tumor effect.